Current biomarkers for ICI therapy across multiple cancer types include PD-L1 expression, TMB, microsatellite instability (MSI) and tumor immune cell infiltration, all of which are related to the tumor and immune cells within the tumor microenvironment (TME).[22–27] However, most of these existing biomarkers have limited sensitivity or specificity and require biopsy samples. Here, CD274 is linked to cancer.